Fly News Breaks for May 19, 2017
May 19, 2017 | 08:28 EDT
BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.
News For AXSM From the Last 2 Days
There are no results for your query AXSM